Skip to content Skip to navigation
University of Warwick
  • Study
  • |
  • Research
  • |
  • Business
  • |
  • Alumni
  • |
  • News
  • |
  • About

University of Warwick
Publications service & WRAP

Highlight your research

  • WRAP
    • Home
    • Search WRAP
    • Browse by Warwick Author
    • Browse WRAP by Year
    • Browse WRAP by Subject
    • Browse WRAP by Department
    • Browse WRAP by Funder
    • Browse Theses by Department
  • Publications Service
    • Home
    • Search Publications Service
    • Browse by Warwick Author
    • Browse Publications service by Year
    • Browse Publications service by Subject
    • Browse Publications service by Department
    • Browse Publications service by Funder
  • Help & Advice
University of Warwick

The Library

  • Login
  • Admin

Treatments for macular oedema following central retinal vein occlusion : systematic review

Tools
- Tools
+ Tools

Ford, John A., Clar, C., Lois, Noemi, Barton, Samantha, Thomas, Sian, Court, Rachel A., Shyangdan, D. and Waugh, Norman (2014) Treatments for macular oedema following central retinal vein occlusion : systematic review. BMJ Open, Volume 4 (Number 2). Article Number e004120. doi:10.1136/bmjopen-2013-004120 ISSN 2044-6055.

[img] PDF
WRAP_BMJ Open-2014-Ford-.pdf - Requires a PDF viewer.
Available under License Creative Commons Attribution Non-commercial.

Download (1171Kb)
Official URL: http://dx.doi.org/10.1136/bmjopen-2013-004120

Request Changes to record.

Abstract

Objectives To review systematically the randomised controlled trial (RCT) evidence for treatment of macular oedema due to central retinal vein occlusion (CRVO).

Data sources MEDLINE, EMBASE, CDSR, DARE, HTA, NHSEED, CENTRAL and meeting abstracts (January 2005 to March 2013).

Study eligibility criteria, participants and interventions RCTs with at least 12 months of follow-up assessing pharmacological treatments for CRVO were included with no language restrictions.

Study appraisal and synthesis methods 2 authors screened titles and abstracts and conducted data extracted and Cochrane risk of bias assessment. Meta-analysis was not possible due to lack of comparable studies.

Results 8 studies (35 articles, 1714 eyes) were included, assessing aflibercept (n=2), triamcinolone (n=2), bevacizumab (n=1), pegaptanib (n=1), dexamethasone (n=1) and ranibizumab (n=1). In general, bevacizumab, ranibizumab, aflibercept and triamcinolone resulted in clinically significant increases in the proportion of participants with an improvement in visual acuity of ≥15 letters, with 40–60% gaining ≥15 letters on active drugs, compared to 12–28% with sham. Results for pegaptanib and dexamethasone were mixed. Steroids were associated with cataract formation and increased intraocular pressure. No overall increase in adverse events was found with bevacizumab, ranibizumab, aflibercept or pegaptanib compared with control. Quality of life was poorly reported. All studies had a low or unclear risk of bias.

Item Type: Journal Article
Subjects: R Medicine > RE Ophthalmology
Divisions: Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Health Sciences
Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School
Library of Congress Subject Headings (LCSH): Eye -- Diseases -- Treatment, Edema -- Treatment, Retina -- Blood vessels -- Diseases, Systematic reviews (Medical research)
Journal or Publication Title: BMJ Open
Publisher: BMJ
ISSN: 2044-6055
Official Date: 2014
Dates:
DateEvent
2014Published
Volume: Volume 4
Number: Number 2
Article Number: Article Number e004120
DOI: 10.1136/bmjopen-2013-004120
Status: Peer Reviewed
Publication Status: Published
Access rights to Published version: Open Access (Creative Commons)

Request changes or add full text files to a record

Repository staff actions (login required)

View Item View Item

Downloads

Downloads per month over past year

View more statistics

twitter

Email us: wrap@warwick.ac.uk
Contact Details
About Us